UY32353A - Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo - Google Patents
Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojoInfo
- Publication number
- UY32353A UY32353A UY0001032353A UY32353A UY32353A UY 32353 A UY32353 A UY 32353A UY 0001032353 A UY0001032353 A UY 0001032353A UY 32353 A UY32353 A UY 32353A UY 32353 A UY32353 A UY 32353A
- Authority
- UY
- Uruguay
- Prior art keywords
- active agent
- effective concentrations
- eye segment
- back eye
- supply effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Compuestos farmacéuticos que contienen tandospirona para la administración ocular tópica. Los compuestos son útiles para suministrar tandospirona al segmento posterior del ojo, a efecto de tratar desordenes que afectan dichos tejidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13970108P | 2008-12-22 | 2008-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32353A true UY32353A (es) | 2010-04-30 |
Family
ID=41559537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032353A UY32353A (es) | 2008-12-22 | 2009-12-21 | Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100160342A1 (es) |
EP (1) | EP2367528A1 (es) |
JP (1) | JP2012513393A (es) |
KR (1) | KR20110099044A (es) |
CN (1) | CN102264344A (es) |
AR (1) | AR074828A1 (es) |
AU (1) | AU2009330517A1 (es) |
BR (1) | BRPI0923502A2 (es) |
CA (1) | CA2747917A1 (es) |
CL (1) | CL2009002197A1 (es) |
MX (1) | MX2011005586A (es) |
RU (1) | RU2011130552A (es) |
TW (1) | TW201028176A (es) |
UY (1) | UY32353A (es) |
WO (1) | WO2010074961A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103664905B (zh) * | 2013-12-25 | 2015-10-14 | 四川科瑞德制药有限公司 | 盐酸坦度螺酮晶型ii及其制备方法 |
CN108619100B (zh) * | 2017-03-16 | 2022-05-13 | 四川科瑞德制药股份有限公司 | 一种氮杂螺酮类药物注射剂及其制备方法和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4407791A (en) * | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
US5286719A (en) * | 1991-10-28 | 1994-02-15 | Mona Industries, Inc. | Phospholipid virucidal compositions |
US5648348A (en) * | 1991-10-28 | 1997-07-15 | Mona Industries, Inc. | Phospholipid antimicrobial compositions |
AU684950B2 (en) * | 1994-05-06 | 1998-01-08 | Alcon Laboratories, Inc. | Use of vitamin E tocopheryl derivatives in ophthalmic compositions |
US5874469A (en) * | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
ATE252369T1 (de) * | 1996-08-09 | 2003-11-15 | Alcon Mfg Ltd | Konservierungssysteme fur cyclodextrine enthaltende arzneimittel |
US6120758A (en) * | 1998-07-16 | 2000-09-19 | Shaklee Corporation | Preservative system for topically applied products |
US20030207890A1 (en) * | 2001-02-23 | 2003-11-06 | Collier Robert J | Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
JP2004262812A (ja) * | 2003-02-28 | 2004-09-24 | Rohto Pharmaceut Co Ltd | 眼圧低下剤 |
US6969706B1 (en) * | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
EP2070518A2 (en) * | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
TWI394564B (zh) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
AR066901A1 (es) * | 2007-05-18 | 2009-09-23 | Alcon Mfg Ltd | Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas |
WO2009114521A1 (en) * | 2008-03-11 | 2009-09-17 | Alcon Research, Ltd. | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
TW201010727A (en) * | 2008-09-03 | 2010-03-16 | Alcon Res Ltd | Pharmaceutical composition having relatively low ionic strength |
-
2009
- 2009-12-08 EP EP09775044A patent/EP2367528A1/en not_active Withdrawn
- 2009-12-08 KR KR1020117016939A patent/KR20110099044A/ko not_active Application Discontinuation
- 2009-12-08 CA CA2747917A patent/CA2747917A1/en not_active Abandoned
- 2009-12-08 US US12/633,322 patent/US20100160342A1/en not_active Abandoned
- 2009-12-08 BR BRPI0923502A patent/BRPI0923502A2/pt not_active IP Right Cessation
- 2009-12-08 WO PCT/US2009/067159 patent/WO2010074961A1/en active Application Filing
- 2009-12-08 AU AU2009330517A patent/AU2009330517A1/en not_active Abandoned
- 2009-12-08 RU RU2011130552/15A patent/RU2011130552A/ru not_active Application Discontinuation
- 2009-12-08 JP JP2011542242A patent/JP2012513393A/ja not_active Withdrawn
- 2009-12-08 CN CN2009801517525A patent/CN102264344A/zh active Pending
- 2009-12-08 MX MX2011005586A patent/MX2011005586A/es not_active Application Discontinuation
- 2009-12-21 UY UY0001032353A patent/UY32353A/es not_active Application Discontinuation
- 2009-12-21 AR ARP090105012A patent/AR074828A1/es unknown
- 2009-12-21 TW TW098143898A patent/TW201028176A/zh unknown
- 2009-12-21 CL CL2009002197A patent/CL2009002197A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009330517A1 (en) | 2010-07-01 |
CN102264344A (zh) | 2011-11-30 |
US20100160342A1 (en) | 2010-06-24 |
JP2012513393A (ja) | 2012-06-14 |
RU2011130552A (ru) | 2013-01-27 |
WO2010074961A1 (en) | 2010-07-01 |
CA2747917A1 (en) | 2010-07-01 |
EP2367528A1 (en) | 2011-09-28 |
CL2009002197A1 (es) | 2011-02-11 |
KR20110099044A (ko) | 2011-09-05 |
AR074828A1 (es) | 2011-02-16 |
MX2011005586A (es) | 2011-06-20 |
BRPI0923502A2 (pt) | 2019-09-24 |
TW201028176A (en) | 2010-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003433A1 (es) | Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014). | |
AR120961A2 (es) | Método y composición para tratar hipertensión ocular y glaucoma | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
BR112012023021A2 (pt) | compostos de indazol e seus usos | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
BR112012013487A2 (pt) | Composições de amantadina e métodos de uso | |
ECSP10010428A (es) | Derivados de indazol | |
UY31294A1 (es) | Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos | |
CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
AR088267A1 (es) | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos | |
ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
MD20140004A2 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia | |
BR112015022084A2 (pt) | composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol | |
GT200900296A (es) | Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante. | |
CL2009002204A1 (es) | Composicion intravenosa biocompatible que comprende un factor de coagulacion incluido en microparticulas de acido alginico o sales del mismo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20201223 |